Probably, but it depends on whether the company can deliver on its cost-cutting potential.
News & Analysis: Fate Therapeutics
Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.
Here's how much you'd have if you'd invested in this mid-cap biotech company that's developing the next generation of cancer immunotherapies.
The cell therapy developer announced the next step for an important pipeline asset.
The company has some additional capital to support the development of its pipeline.
Here's what's behind two of the most exciting stocks in the gene therapy sector.
This mid-cap biotech is developing a new type of cellular immunotherapy, and its potential has attracted the attention of many institutional investors.
FATE earnings call for the period ending March 31, 2020.
The cell therapy pioneer has a promising early-stage pipeline and just landed a huge partner. What should investors make of this high-risk, high-reward stock?
The development-stage pharma company gave up a good chunk of its gains from recent months, but roared back in April.